- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01330966
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
March 8, 2023 updated by: George Clinical Pty Ltd
A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This research study is being conducted in adult subjects with a type of bone cancer called chondrosarcoma that has spread to other parts of the body and is not able to be removed with surgery.
There is only one study drug that will be used in this study.
It is a drug that interferes with cell communication and growth, taken orally.
The study drug is called pazopanib.
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Birmingham
-
Edgbaston, Birmingham, United Kingdom, B15 2TH
- University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre
-
-
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
-
Illinois
-
Naperville, Illinois, United States, 60540
- Edward Cancer Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19106
- Pennsylvania Oncology Hematology Associates
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent.
- Age > or = to 18 years.
- Histologically confirmed diagnosis of conventional chondrosarcoma of any grade.
- Surgically unresectable or metastatic disease.
- Any number of prior treatment regimens, including treatment naive subjects. Prior treatment with tyrosine kinase inhibitors is permitted.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
- Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1.
- Adequate organ system function determined within 14 days prior to first dose of study treatment.
- Left ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment.
- Females must either be of non-child bearing potential or have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.
Exclusion Criteria:
- Prior treatment with pazopanib.
- Mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes.
- Prior malignancy (Note: subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible).
- History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, unless previously treated, asymptomatic, and off steroids and anti-seizure medication for 6 months prior to first dose of study drug.
- Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding.
- Clinically significant GI abnormalities that may affect absorption of investigational product.
- Presence of uncontrolled infection.
- Corrected QT interval > 480 msecs using Bazett's formula.
- History of certain cardiovascular conditions within the past 6 months.
- Poorly controlled hypertension [defined as systolic blood pressure of > or = 140 mmHg or diastolic blood pressure of > or = 90 mmHg].
- History of cerebrovascular accident including transient ischemic attack, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months.
- Prior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer.
- Evidence of active bleeding or bleeding diathesis.
- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage.
- Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures.
- Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of study treatment.
- Radiation therapy, surgery (except major surgery), tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug.
- Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: pazopanib
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
|
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control at Week 16
Time Frame: Assessed at week 16 of study treatment
|
Disease control at week 16 defined as complete response (CR), Disappearance of all target lesions; plus partial response (PR), At least a 30% decrease in the sum of diameters of the target lesions taking as reference the Baseline sum diameters; plus stable disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on the study; where tumor response is defined by RECIST (Response Evaluation Criteria in Solid Tumors) guidelines version 1.1.
Repeat radiologic imaging is performed after every 2 cycles of treatment (approximately every 8 weeks).
|
Assessed at week 16 of study treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression Free Survival (PFS)
Time Frame: Cycle 1 day 1 until the subject experiences disease progression
|
The time origin for PFS will be cycle 1 day 1.
Repeat radiologic imaging will be conducted after every 2 cycles of treatment (approximately every 8 weeks).
No upper limits of duration of assessment are identified or defined in the protocol.
|
Cycle 1 day 1 until the subject experiences disease progression
|
Overall Survival (OS)
Time Frame: Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent
|
The time origin for OS will be cycle 1 day 1.
Subjects will be followed until 6 months after end of treatment, lost to follow-up, or withdrawal of consent.
No upper limits of duration of assessment are identified or defined in the protocol.
|
Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Arthur Staddon, MD, Pennsylvania Oncology Hematology Associates
- Study Chair: Warren Chow, MD, City of Hope Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2011
Primary Completion (Actual)
February 1, 2018
Study Completion (Actual)
February 1, 2018
Study Registration Dates
First Submitted
April 6, 2011
First Submitted That Met QC Criteria
April 6, 2011
First Posted (Estimate)
April 7, 2011
Study Record Updates
Last Update Posted (Estimate)
March 10, 2023
Last Update Submitted That Met QC Criteria
March 8, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAPSMCS1002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chondrosarcoma
-
National Cancer Institute (NCI)Active, not recruitingMesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Clear Cell Chondrosarcoma | Locally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Primary Central ChondrosarcomaFrance
-
Leiden University Medical CenterCompletedMyxoid Liposarcoma | Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Conventional ChondrosarcomaSpain, Netherlands
-
National Cancer Institute (NCI)Active, not recruitingDedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central ChondrosarcomaUnited States, Canada
-
National Cancer Institute (NCI)SuspendedMetastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central ChondrosarcomaUnited States
-
Memorial Sloan Kettering Cancer CenterAgios Pharmaceuticals, Inc.RecruitingChondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3United States
-
Italian Sarcoma GroupPharmaMarRecruitingMesenchymal ChondrosarcomaItaly
-
Istituto Ortopedico RizzoliCompleted
-
Washington University School of MedicineWithdrawn
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI)Active, not recruitingChordoma of Sacrum | Chordoma of Spine | Chordoma of Base of Skull | Chondrosarcoma of the Spine | Chondrosarcoma of the SacrumUnited States
-
Istituto Ortopedico RizzoliCompleted
Clinical Trials on pazopanib
-
Cure HHTUniversity of North CarolinaNot yet recruitingEpistaxis | Hereditary Hemorrhagic Telangiectasia
-
Illinois CancerCare, P.C.TerminatedNon Small Cell Lung CancerUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...CompletedMetastatic Renal Cell Carcinoma
-
Institut Claudius RegaudNovartisTerminatedMetastatic Cancer (Different Solid Tumour Types)France
-
Gynecologic Oncology GroupGlaxoSmithKlineWithdrawnUterine Leiomyosarcoma
-
Samsung Medical CenterCompletedRefractory Solid TumorsKorea, Republic of
-
Spanish Oncology Genito-Urinary GroupCompletedMetastatic Renal Cell CarcinomaSpain
-
GlaxoSmithKlineCompletedMacular DegenerationUnited States
-
Samsung Medical CenterCompletedLocally Advanced or Metastatic Non-clear Cell Type Renal Cell CarcinomaKorea, Republic of
-
Samsung Medical CenterCompletedNeuroendocrine TumorKorea, Republic of